For instance, adult patients with anti-TIF1 autoantibodies exhibit a significantly heightened risk of malignancy compared to other DM patients but have a low propensity for developing interstitial lung disease (ILD).(7) Conversely, those with MDA5 autoantibodies frequently have ILD but only rarely have a coexisting cancer.(3) While each DM patient is thought to have only a single MSA, anti-Mi2 autoantibodies have shown low-level binding to TIF1γ, posing challenges for the development of a specific immunologic assay for anti-TIF1γ autoantibodies.(8). This evidence concerns the gene TRIM33 and dermatomyositis.